Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ian Schofield

Executive Editor

Edinburgh, UK
Ian specialises in pharmaceutical regulatory affairs, mainly in the EU and the UK but also in Australia, New Zealand, Canada and certain African markets. His key areas of focus are clinical trials, market access, intellectual property issues, global regulatory alignment and pandemic preparedness. A modern languages graduate, he worked in the European travel industry before joining Scrip in 1985 as a reporter covering the French and Italian markets. He subsequently held posts including Deputy Editor of Scrip and Principal Analyst at Informa, before taking up his current position at the Pink Sheet. As well as writing news, features and analysis, Ian is part of the Ask the Analyst team that produces on-demand tailored reports for subscribers. His non-work interests include cycling, travel, paddleboarding and playing traditional Scottish music.

Latest From Ian Schofield

COVID-19 Has ‘Permanently Changed’ How The EMA Works

Coronavirus COVID-19 Europe

UK Industry ‘Struggling’ With Skill Gaps In AI, Robotics & Data Analytics

A new report says that pharma firms are finding it difficult to recruit staff with experience in emerging scientific technologies, particularly in areas such as regulatory and quality assurance. COVID-19, Brexit and competition for talent with other countries and industry sectors are cited as key factors.

Europe United Kingdom

Canada Proposes List Of ‘Critical Products’ & More Agile Regulation To Address Shortages

The Canadian government says stakeholders are “poised for action” to improve the collective response to medical product shortages and has come up with some questions and possible answers as to how best to go about it.

Canada Supply Chain

EMA Agrees Monovalent XBB Vaccines Best For Coming COVID-19 Campaigns

The European Medicines Agency says it is talking with international partners and pharmaceutical companies about the epidemiological situation with SARS-CoV-2 and how authorized COVID-19 vaccines can best be adapted to emerging variants.

Canada Proposes List Of ‘Critical Products’ & More Agile Regulation To Address Shortages

The Canadian government says stakeholders are “poised for action” to improve the collective response to drug shortages and has come up with some questions and possible answers as to how best to go about it.

Canada Supply Chain

What Would An EU ‘Regulatory Sandbox’ Bring To New Drug Development?

Digital health, AI, real-world evidence and “proactive learning” are key components of the EU’s proposals for new ways of regulating novel medicines, but only time will tell which products might benefit from the flexibilities offered by the “regulatory sandbox.”

Europe Regulation
See All
UsernamePublicRestriction

Register